Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists
US9289436B2 · kind B2 · utility
51Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 21, 2013 |
| Grant date | Mar 22, 2016 |
| Priority date | — |
| Expiry date | Feb 21, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.